Story thread · 4 reports / 4 sources
FDA approves new ADHD medication: 4 things to know
beckershospitalreview.com · 14d
How the coverage leans
Across 4 sources · syndicated copies counted once
The FDA approved Simtriyo (centanafadine), making it the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older weighing at least 20 kilograms, according to a July 24 news release from Otsuka Pharmaceutical. Here are four things to […] The post FDA approves new ADHD medication: 4 things to know appeared first on Becker's Hospital Review | Healthcare News & Analysis .
First report: First-in-Class Drug for ADHD Wins FDA Approval — medpagetoday.com, 15d
The coverage
- FDA Approves First NDSRI for ADHD in Adults and Children
medscape.com · 15d
- A new ADHD drug just got FDA approval. Here's what makes it different.
mdjonline.com · 15d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.